What is 10x Genomics Inc - Ordinary Shares - Class A Annual Revenue?

10x Genomics Inc - Ordinary Shares - Class A Annual Revenue fell 1.28%, in the last year to $610.78 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

What is 10x Genomics Inc - Ordinary Shares - Class A Annual Net Profit?

10x Genomics Inc - Ordinary Shares - Class A Annual Net Profit rose 28.41% in the last year to $182.63 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

What is 10x Genomics Inc - Ordinary Shares - Class A Price to Earning Ratio?

10x Genomics Inc - Ordinary Shares - Class A Price to Earning Ratio is -6.96, which is negative.

What is 10x Genomics Inc - Ordinary Shares - Class A Stock Price?

10x Genomics Inc - Ordinary Shares - Class A Stock Price fell 71.37% and underperformed its sector by 81.27% in the past year.

What is 10x Genomics Inc - Ordinary Shares - Class A Quarterly Revenue?

10x Genomics Inc - Ordinary Shares - Class A Quarterly Revenue fell 10.3% YoY to $165.02 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is 10x Genomics Inc - Ordinary Shares - Class A Quarterly Net profit?

10x Genomics Inc - Ordinary Shares - Class A Quarterly Net profit fell 0.16% YoY to $49.03 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

What is 10x Genomics Inc - Ordinary Shares - Class A Debt to Equity Ratio?

10x Genomics Inc - Ordinary Shares - Class A Debt to Equity Ratio of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is 10x Genomics Inc - Ordinary Shares - Class A Return on Equity(ROE)?

10x Genomics Inc - Ordinary Shares - Class A Return on Equity(ROE) for the last financial year was -25.17%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is 10x Genomics Inc - Ordinary Shares - Class A Mutual Fund Holding?

10x Genomics Inc - Ordinary Shares - Class A Mutual Fund Holding increased by 0.19% in the last quarter to 68.07.

What is 10x Genomics Inc - Ordinary Shares - Class A Promoter Share Holding?

10x Genomics Inc - Ordinary Shares - Class A Promoter Share Holding increased by 3.29% in the most recent quarter to 10.98%.

What is 10x Genomics Inc - Ordinary Shares - Class A Interest Coverage Ratio?

10x Genomics Inc - Ordinary Shares - Class A Interest Coverage Ratio is -44424, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is 10x Genomics Inc - Ordinary Shares - Class A Institutional Holding?

10x Genomics Inc - Ordinary Shares - Class A Institutional Holding remained the same in the last quarter at 89.3%.

How is the 10x Genomics Inc - Ordinary Shares - Class A today?

The 10x Genomics Inc - Ordinary Shares - Class A today is trading in the down by 0.00% at 10.39.

How has 10x Genomics Inc - Ordinary Shares - Class A performed historically?

The 10x Genomics Inc - Ordinary Shares - Class A is currently trading down 0.00% on an intraday basis in the past week the index fell -3.44%. The index has been down -29.18% in the past quarter and fell -71.37% in the past year. You can view this in the overview section.

10x Genomics Inc - Ordinary Shares - Class A XNAS: TXG

10x Genomics Inc - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

Name: 10x Genomics Inc - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: 10x Genomics Inc - Ordinary Shares - Class A
Rating: 1.45883325
Author: Trendlyne DVM scores

Weak Stock

Download real time

10.39 0.00 (0.00%)

73.01% Fall from 52W High

2.7M XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

10x Genomics Inc - Ordinar... Key Metrics

My Metrics

Select

Market Capitalization High in industry Unavailable in chosen country	1,270.7
PE TTM Negative PE TTM Unavailable in chosen country	-7
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.2
Price to Book Below industry Median Unavailable in chosen country	1.8
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	89.3
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-10.3
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-1.3
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-0.2
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	28.4
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-30.2
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-31.9
Piotroski Score High in industry Unavailable in chosen country	5
Rel Perf vs Sector quarter% Unavailable in chosen country	-36.4
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-25.2
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-19.4

All financials are in USD Million and price data in USD

Low Financial Strength

33.3 / 100

Expensive Valuation

21.0 / 100

Technically Bearish

29.0 / 100

Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 54%

14 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

10x Genomics Inc - Ordinar... Stock Price Analysis

Week Price Range -3.4% 1 Week return Unavailable in chosen country	10.4 (LTP) 9.610.8 LowHigh
Month Price Range -8.0% 1 Month return Unavailable in chosen country	10.4 (LTP) 9.311.9 LowHigh
52 Week Price Range -71.4% 1 Year return Unavailable in chosen country	10.4 (LTP) 9.338.5 LowHigh

View full Share Price History

10x Genomics Inc - Ordinar... Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

10x Genomics Inc - Ordinary Shares - Class A's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-1.5

Avg. Estimate

-1.5

Low Estimate

-1.8

High Estimate

-1.1

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 2.0% in FY25

Consensus Recommendation

17 ANALYST Recommendations

BUY

The consensus recommendation from 17 analysts for 10x Genomics Inc - Ordinary Shares - Class A is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

10x Genomics Inc - Ordinar... Stock Analysis

10x Genomics Inc - Ordinar... stock analysis with key metrics, changes, and trends.

10x Genomics Inc - Ordinar... Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$610.78 M	1.28%	negative	Annual Revenue fell 1.28%, in the last year to $610.78 M. Its sector's average revenue growth for the last fiscal year was 7.46%.
Annual Net Profit	$182.63 M	28.41%	positive	Annual Net Profit rose 28.41% in the last year to $182.63 M. Its sector's average net profit growth for the last fiscal year was -32.46%.
Price to Earning Ratio	-6.96	-	negative	Price to Earning Ratio is -6.96, which is negative.
Stock Price	$10.39	-71.37%	negative	Stock Price fell 71.37% and underperformed its sector by 81.27% in the past year.
Quarterly Revenue	$165.02 M	10.3%	negative	Quarterly Revenue fell 10.3% YoY to $165.02 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$49.03 M	0.16%	negative	Quarterly Net profit fell 0.16% YoY to $49.03 M. Its sector's average net profit growth YoY for the quarter was -47.25%.
Debt to Equity Ratio	0.12	-	positive	Debt to Equity Ratio of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-25.17 %	-25.17%	negative	Return on Equity(ROE) for the last financial year was -25.17%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	68.07 %	0.19%	positive	Mutual Fund Holding increased by 0.19% in the last quarter to 68.07.
Promoter Share Holding	10.98 %	3.29%	positive	Promoter Share Holding increased by 3.29% in the most recent quarter to 10.98%.
Interest Coverage Ratio	-44424	-	negative	Interest Coverage Ratio is -44424, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	89.30 %	0%	neutral	Institutional Holding remained the same in the last quarter at 89.3%.

VIEW LESS

Loading data..

10x Genomics Inc - Ordinary Shares - Class A - Company Profile

What does 10x Genomics Inc - Ordinary Shares - Class A do?

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Gross Remuneration

2024

Gross Remuneration

Year

10x Genomics Inc - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

73.01% Fall from 52W High

10x Genomics Inc - Ordinar... Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

10x Genomics Inc - Ordinar... Stock Price Analysis

Week Price Range

Month Price Range

52 Week Price Range

10x Genomics Inc - Ordinar... Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

10x Genomics Inc - Ordinary Shares - Class A's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 2.0% in FY25

Consensus Recommendation

The consensus recommendation from 17 analysts for 10x Genomics Inc - Ordinary Shares - Class A is BUY

10x Genomics Inc - Ordinar... Stock Analysis

10x Genomics Inc - Ordinar... stock analysis with key metrics, changes, and trends.

Annual Revenue fell 1.28%, in the last year to $610.78 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit rose 28.41% in the last year to $182.63 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio is -6.96, which is negative.

Stock Price fell 71.37% and underperformed its sector by 81.27% in the past year.

Quarterly Revenue fell 10.3% YoY to $165.02 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit fell 0.16% YoY to $49.03 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Debt to Equity Ratio of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -25.17%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.19% in the last quarter to 68.07.

Promoter Share Holding increased by 3.29% in the most recent quarter to 10.98%.

Interest Coverage Ratio is -44424, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding remained the same in the last quarter at 89.3%.

10x Genomics Inc - Ordinary Shares - Class A - Company Profile

What does 10x Genomics Inc - Ordinary Shares - Class A do?

10x Genomics Inc - Ordinary Shares - Class A Management structure

Mr. James L. Wilbur

Chief Commercial Officer

Mr. Justin J. McAnear

Chief Financial Officer and Principal Accounting Officer

Ms. Mennah Moustafa

Chief Commercial Officer

Mr. Adam S. Taich

Chief Financial Officer and Principal Accounting Officer

Dr. Serge Saxonov, PhD

Chief Executive Officer and Director

Dr. Benjamin J. Hindson, PhD

Director, Chief Scientific Officer and President

10x Genomics Inc - Ordinary Shares - Class A Board of directors

Mr. Alan V. Mateo

Director